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Transgenic Parasites Stably Expressing Full-Length Plasmodium
falciparum Circumsporozoite Protein as a Model for Vaccine Down-
Selection in Mice Using Sterile Protection as an Endpoint
Michael D. Porter,a Jennifer Nicki,a Christopher D. Pool,a Margot DeBot,a Ratish M. Illam,a Clara Brando,b Brooke Bozick,b
Patricia De La Vega,a Divya Angra,a Roberta Spaccapelo,c Andrea Crisanti,d Jittawadee R. Murphy,b Jason W. Bennett,a
Robert J. Schwenk,a Christian F. Ockenhouse,a Sheetij Duttaa
Malaria Vaccine Development Brancha and Entomology Branch,b Walter Reed Army Institute of Research, Silver Spring, Maryland, USA; Università degli Studi di Perugia,
Perugia, Italyc; Imperial College London, London, United Kingdomd
Circumsporozoite protein (CSP) of Plasmodium falciparum is a protective human malaria vaccine candidate. There is an urgent
need for models that can rapidly down-select novel CSP-based vaccine candidates. In the present study, the mouse-mosquito
transmission cycle of a transgenic Plasmodium berghei malaria parasite stably expressing a functional full-length P. falciparum
CSP was optimized to consistently produce infective sporozoites for protection studies. A minimal sporozoite challenge dose was
established, and protection was defined as the absence of blood-stage parasites 14 days after intravenous challenge. The specific-
ity of protection was confirmed by vaccinating mice with multiple CSP constructs of differing lengths and compositions. Con-
structs that induced high NANP repeat-specific antibody titers in enzyme-linked immunosorbent assays were protective, and the
degree of protection was dependent on the antigen dose. There was a positive correlation between antibody avidity and protec-
tion. The antibodies in the protected mice recognized the native CSP on the parasites and showed sporozoite invasion inhibitory
activity. Passive transfer of anti-CSP antibodies into naive mice also induced protection. Thus, we have demonstrated the utility
of a mouse efficacy model to down-select human CSP-based vaccine formulations.
Amalaria parasite-infected mosquito injects approximately 10to 200 sporozoites into a vertebrate host’s skin during a blood
meal (1). These sporozoites travel to the liver, where each success-
ful invasion of a liver hepatocyte yields approximately 30,000
blood-stage merozoites (2). Hence, immune interventions that
block sporozoite invasion are thought currently to be the most
effective way to protect against malaria. The most abundant Plas-
modium falciparum sporozoite surface protein is the 397-amino
acid circumsporozoite protein (CSP). Genetic analysis of CSP
from multiple Plasmodium species reveals a highly conserved
structure (3). The central region of CSP is composed of species-
specific repeats that are flanked by an amino-terminal region, re-
gion I, containing a conserved five-amino-acid sequence and a
carboxyl-terminal region, region II, containing a conserved cell
adhesion motif similar to that observed in the mammalian throm-
bospondin protein (4).
Malaria still causes extensive morbidity and mortality, and the
development of a vaccine against this parasite is an urgent research
priority. Because of its abundance and exposed location on the
sporozoite surface, CSP has been widely investigated as a candi-
date malaria vaccine antigen. RTS,S, the most advanced human
malaria vaccine candidate to date, contains the central repeats and
the cysteine-rich C-terminal region of Plasmodium falciparum
CSP (PfCSP). Vaccination with RTS,S induces sterile protection
against experimental sporozoite challenge in about 50% of vaccin-
ees (5); this vaccine is now undergoing advanced phase III trials at
multiple centers in Africa. Although RTS,S marked a critical point
as a proof-of-concept recombinant protein vaccine against ma-
laria, the efficacy and duration of RTS,S-based protection are not
sufficient to eradicate the disease. It is hypothesized that a full-
length CSP-based vaccine might confer improved protection by
eliciting immune responses to the N-terminal region of CSP, an-
tibodies against which have been associated with protection from
disease (6).
Although nonhuman primates are considered the best model
to predict human protection against malaria, these models are
costly and often require splenectomy of the monkeys. Moreover,
the few P. falciparum strains that have been shown to infect New
World monkeys do not match the commonly used vaccine strain
3D7 (7–9). Although transgenic monkey parasites expressing a
full-length P. falciparum CSP would be ideal, none is currently
available for use. Several reports suggest that transgenic rodent
parasites expressing the P. falciparum CSP gene are viable and
infective in mice. One such parasite, in which the central repeat
region of Plasmodium berghei CSP was exchanged with that of P.
falciparum, has been used recently to evaluate the protective effi-
cacy of P. falciparum CSP vaccines in mice (10, 11). However, such
parasites provide no information on the protective role of the N-
and C-terminal epitopes of CSP. Furthermore, the outcomes of
these murine challenge studies might be clouded by measurement
of the reduction of parasite-specific RNA, rather than direct as-
sessment of protective efficacy. To address these issues, we have
optimized a vaccine evaluation model based on a previously de-
scribed transgenic parasite in which the full-length P. berghei CSP
gene was replaced with P. falciparum CSP (4). This parasite line
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was originally produced to study the structure-function relation-
ship of CSP during salivary gland and hepatocyte invasion. While
the full-length CSP-transgenic sporozoites showed reduced sali-
vary gland invasion, the mouse infectivity of these parasites was
similar to that of wild-type P. berghei sporozoites (4). Our data
indicate that this full-length transgenic parasite is usable for rapid
down-selection of recombinant P. falciparum CSP-based vac-
cines, with sterile protection as an endpoint.
MATERIALS AND METHODS
Recombinant CSP vaccination. The genes for the CSP constructs used to
immunize mice were codon optimized for high-level expression in Esch-
erichia coli using the 3D7 strain CSP sequence (GenBank accession num-
ber XM_001351086.1). The histidine-tagged proteins from the soluble
fraction were purified to homogeneity using chromatography columns
(purification process to be presented elsewhere). The endotoxin content
of the vaccine proteins was less than 5 endotoxin units/g, as measured
with the Limulus amebocyte lysate endotoxin assay (Associates of Cape
Cod, East Falmouth, MA). The antigens were mixed with Montanide
ISA720 adjuvant (Seppic Inc., Paris, France) in a 3:7 (vol/vol) antigen/
adjuvant ratio, and the formulation was emulsified by vigorous vortex
mixing for 10 to 15 min. One hundred microliters of vaccine was admin-
istered to C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME) in-
traperitoneally, and three immunizations were given at 2-week intervals.
Mice were bled 2 weeks after each vaccination. IgG used in the passive
transfer experiment was pooled from three rabbits that had been vacci-
nated three times with 100 g of N-(NANP)19-C protein emulsified with
Montanide ISA720 adjuvant, at 4-week intervals.
Adaptation of transgenic P. berghei in the rodent and mosquito
hosts. Transgenic (Tr) P. berghei parasites, previously described by Tewari
et al. (4), were obtained and injected intraperitoneally into three outbred
mice. Six days following inoculation, the presence of blood-stage para-
sitemia was confirmed by Giemsa-stained blood smear examination.
Blood from one infected mouse was collected and diluted 1:1 with phos-
phate-buffered saline (PBS), and 0.2 ml was injected into three naive mice
to start blood passage cycle 1 (BP-1) (Fig. 1A). Three days postinfection,
200 to 300 female Anopheles stephensi mosquitoes were allowed to feed on
two of the three BP-1-infected mice, while the third mouse was used to
generate a cohort of BP-2-infected mice via infected blood transfer. This
process was repeated until the fourth blood passage, at which point three
naive mice were inoculated with infectious sporozoites via mosquito bites,
thus generating a new set for which the cycle of four blood passages was
repeated.
Oocyst and sporozoite ratings. The oocyst and sporozoite data from
10 cycles, each consisting of four blood passages, were collected and sta-
tistically analyzed to determine infectivity differences between the wild-
FIG 1 Transgenic P. berghei optimization in the mosquito-mouse model. (A) Passage cycles of the transgenic P. berghei parasite (Tr-Pb) from mouse to
mosquito. Data from 10 mosquito-mouse cycles, each consisting of 4 blood passages, were collected. (B) Percentage of mosquitoes infected with oocysts and
sporozoites of transgenic or wild-type P. berghei parasites. Means  standard errors of the mean (SEM) and Mann-Whitney P values are shown. (C) Oocyst and
sporozoite ratings (means  SEM). Oocyst ratings were defined as follows: 0, 0 oocysts; 1, 1 to 25 oocysts per midgut; 2, 26 to 50 oocysts per midgut; 3, 51 to 100
oocysts per midgut; and 4, 100 oocysts per midgut. Sporozoite load ratings were defined as follows: 0, 0 sporozoites; 1, 1 to 100 sporozoites per mosquito; 2, 100
to 1,000 sporozoites per mosquito; 3, 1,000 to 10,000 sporozoites per mosquito; and 4, 10,000 sporozoites per mosquito. (D) Sporozoite yield per mosquito
using mouse-mouse blood transmission or mouse-mosquito (vector-borne) transmission. (E) Reactivity of anti-P. berghei CSP MAb 4B10 (anti-PbCS) and
anti-P. falciparum CSP MAb 49-1B2 (anti-PfCS) against Tr P. berghei (Pf-Pb) and WT P. berghei (Pb) sporozoites.
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type and transgenic parasites. At 8 to 11 days after feeding on parasitemic
mice, 10 mosquitoes were randomly sampled from each carton, and their
midguts were removed and stained with methylene blue. Oocyst ratings
were defined as follows: 0, 0 oocysts; 1, 1 to 25 oocysts; 2, 26 to 50 oocysts;
3, 51 to 100 oocysts; 4, 100 oocysts. Eighteen days after the infectious
blood meal, salivary glands dissected from 10 mosquitoes were examined
for the presence and estimated quantity of sporozoites. Sporozoite ratings
were defined as follows: 0, 0 sporozoites; 1, 1 to 100 sporozoites per mos-
quito; 2, 100 to 1,000 sporozoites per mosquito; 3, 1,000 to 10,000 sporo-
zoites per mosquito; and 4, 10,000 sporozoites per mosquito.
Isolation of sporozoites for challenge and passive transfer. Fresh
naive mouse serum was isolated from whole blood using serum separator
tubes (Becton, Dickinson and Co., Franklin Lakes, NJ) and was used to
supplement RPMI 1640 medium (BioWhittaker, Walkersfield, MD) to a
final concentration of 5% (vol/vol) (RPMI/serum). Sporozoites were col-
lected using the method described by Ozaki et al. (12). Briefly, a hole was
punctured at the bottom of a 0.5-ml siliconized Eppendorf tube and
plugged with a small amount of glass wool, and the tube was placed inside
a larger, 1.5-ml, siliconized Eppendorf collection tube. Mosquitoes were
killed by immersion in 70% ethanol for approximately 1 min, rinsed with
tap water, and bathed in a small volume of RPMI/serum. Dissections were
performed in a drop of RPMI/serum under a dissecting microscope.
Heads plus salivary glands were gently separated from the thoraxes, and
up to 50 heads were added per Ozaki tube. One hundred microliters
RPMI/serum was added, followed by centrifugation at 9,000  g for 2
min. The sporozoite pellet was resuspended in the eluate and transferred
to another Eppendorf tube. Another 100 l of RPMI/serum was added to
the original tube, which was respun at 9,000  g for 2 min, and the pellet
was combined with the initial recovery. The sporozoites were stored on ice
after isolation. Sporozoites were counted with a hemocytometer and di-
luted to 25,000 per ml in RPMI/serum, and 100 l of this suspension was
injected intravenously into the lateral tail vein of each mouse. In the pas-
sive transfer experiment, mice were injected intraperitoneally with 1 mg of
protein G (GE Healthcare, Pittsburgh, PA)-purified rabbit anti-PfCSP
IgG or 1 mg of rabbit anti-P. falciparum apical membrane antigen 1 con-
trol IgG. A second dose of IgG was given the next morning, and mice were
challenged with 2,500 sporozoites 5 h later.
Monitoring of mouse infection. Levels of parasitemia in the mice
were monitored daily using thin blood smears, from day 5 to day 14
postchallenge. Blood smears were fixed with methanol and stained with
Giemsa stain. Positive infection in mice was defined as the appearance of
two parasites in 25 high-power fields (100 magnification). Mice found
to be infected with blood stages of the parasite (not protected) were sac-
rificed, and mice that did not develop blood-stage parasitemia by day 14
were reported as being protected.
ELISA. Immulon 2HB plates (Thermo Scientific, Rochester, NY) were
coated overnight at 4°C with either 50 ng/well recombinant CSP [N-
(NANP)19-C] or 20 ng/well (NANP)6 peptide. Plates were washed with
PBS containing 0.05% Tween 20 (PBS/T) and blocked for 1 h with PBS
containing 1% casein. Fifty microliters of diluted primary antibody was
added to the wells in duplicate for 2 h at 22°C, plates were washed 3 times
with PBS/T, and 50 l/well of a 1:15,000 dilution of peroxidase-conju-
gated anti-mouse IgG (Southern Biotech, Birmingham, AL) was added.
After 1 h of incubation, plates were washed 4 times with PBS/T and de-
veloped using 50 l/well ABTS [2,2=-azinobis(3-ethylbenzthiazolinesul-
fonic acid)] peroxidase substrate system (KPL, Gaithersburg, MD) for 1 h.
The optical density at 415 nm (OD415) was measured using a Synergy4
microplate reader (BioTek, Highland Park, VT) and the endpoint titer,
defined as the serum dilution that resulted in an OD415 value of 1.0, was
calculated using Gen5 software (BioTek). The avidity enzyme-linked im-
munosorbent assay (ELISA) was performed similarly, with 75 l of a
1:1,000 serum dilution added to the blocked wells for 1 h. After washing,
100 l of either 6 M urea or PBS was incubated in the wells for 10 min.
Plates were washed, and the rest of the ELISA procedure was performed as
described above. The avidity index was defined as the ratio of OD415
values obtained in the presence and absence of 6 M urea.
Indirect immunofluorescence assay. Sporozoites were placed on an
immunofluorescence assay (IFA) slide, air dried, and fixed with chilled
methanol for 1 min. Wells were blocked with PBS containing 5% bovine
serum albumin, and serial dilutions of the test antibodies were added and
incubated for 2 h. Slides were washed 3 times with PBS and incubated with
a 1:100 dilution of fluorescein-labeled anti-mouse IgG (Southern Bio-
tech) for 1 h. The slides were washed again, and anti-fade solution (Mo-
lecular Probes, Eugene, OR) was applied. Fluorescence was observed with
a UV microscope (200 magnification). An adjuvant control serum pool
diluted 1:100 was used as a negative control. The mouse P. berghei CSP
(PbCSP)-specific monoclonal antibody (MAb) 4B10 and the PfCSP-spe-
cific MAb 49-1B2 were used in the study.
Sporozoite invasion inhibition assay. Mouse serum was tested for its
ability to inhibit sporozoite entry into hepatocytes (13). Briefly, the wells
of a Lab-Tek glass chamber slide were coated with entactin-collagen IV-
laminin (ECL) attachment matrix (Millipore, Billerica, MA), 45,000
HepG2-A16 cells were added, and the slide was incubated overnight at
37°C in 5% CO2. Fifty microliters of the appropriate serum dilution, along
with 50 l of P. falciparum NF54 sporozoite suspension (25,000 sporozo-
ites), was added per well. The chamber slides were then incubated for 3 h
at 37°C in 5% CO2. Slides were washed with PBS and fixed with chilled
methanol. Sporozoites that had invaded hepatocytes were visualized by
staining with a P. falciparum CSP-specific MAb (49-1B2), followed by the
addition of a 1:200 dilution of horseradish peroxidase-conjugated goat
anti-mouse IgG secondary antibody (KPL, Gaithersburg, MD). Color was
developed using 3,3=-diaminobenzidine reagent (KPL), and slides were
mounted with Permount mounting medium (Fisher Scientific, Hampton,
NH). The number of intracellular sporozoites per well was counted with a
phase-contrast microscope at 200 magnification. The percent inhibi-
tion of sporozoite invasion was calculated as (invasion events in the me-
dium control  invasion events in the test serum)/invasion events in the
medium control  100.
Native CSP Western blotting. Proteins from 50,000 sporozoites per
well were separated by SDS-PAGE, electrophoretically transferred to a
nitrocellulose membrane, and blocked for 1 h with PBS with casein. The
blot was incubated with a 1:1,000 dilution of immune serum for 1 h,
washed with PBS/T, and incubated for 1 h with a 1:5,000 dilution of
alkaline phosphatase-conjugated anti-mouse IgG secondary antibody
(Southern Biotech). The blots were washed again and developed with
nitroblue tetrazolium-5-bromo-4-chloro-3-indolylphosphate sub-
strate tablets (Roche, Nutley, NJ).
Statistical analysis. Data were plotted using Excel (Microsoft, Red-
mond, WA) and GraphPad Prism (GraphPad Software Inc., La Jolla, CA).
Unpaired groups of data were compared for significant differences utiliz-
ing Mann-Whitney nonparametric tests. P values of 0.05 were used to
determine statistical significance.
RESULTS
Adaptation of the transgenic P. berghei parasite in the mouse
and mosquito hosts. Data from 10 independent mosquito-mouse
transmission cycles showed no significant differences in the per-
centages of mosquitoes infected with oocysts and in the oocyst
ratings between transgenic P. berghei-infected and wild-type
(WT) P. berghei-infected mosquitoes (Fig. 1B and C). However,
the percentage of mosquitoes infected with salivary gland sporo-
zoites and the mean sporozoite ratings (on a scale of 0 to 4) were
significantly lower for Tr P. berghei-infected mosquitoes (Mann-
Whitney test, P  0.05 for both comparisons). Initial batches ob-
tained by feeding mosquitoes on mice that were infected by blood
stages typically yielded 500 sporozoites per mosquito, compared
with 10,000 sporozoites for the WT P. berghei-infected mosqui-
toes. The transmission cycle was then modified, eliminating the
Model to Down-Select Human Malaria Vaccines
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blood-stage transmission, and mosquitoes were fed only on mice
that had been infected directly by mosquito bites. This modifica-
tion selected for a line that was better adapted to produce salivary
gland sporozoites, increasing the average yield to 2,000 sporo-
zoites per mosquito (Fig. 1D). However, no change in the rodent
infectivity of the adapted parasites was notable. The genetic re-
placement of the PbCSP gene with PfCSP was confirmed by IFA
using a P. falciparum-specific monoclonal antibody (MAb), 49-
1B2. WT P. berghei sporozoites reacted with a PbCSP-specific
MAb, 4B10, but only weak reactivity was observed with the PfCSP-
specific MAb 49-1B2 (Fig. 1E). In contrast, the Tr P. berghei sporo-
zoites reacted only with the PfCSP-specific MAb.
Challenge route and dose optimization. To reproduce the
natural mode of transmission used for experimental human chal-
lenges, either 5 or 10 Tr P. berghei sporozoite-infected mosquitoes
were fed on individual C57BL/6 mice. This challenge route yielded
variable infectivity data that were strongly dependent on the
sporozoite loads of individual mosquitoes in the carton. A subcu-
taneous challenge using isolated sporozoites also showed low in-
fectivity, despite a high sporozoite inoculum (Table 1, experi-
ments I and II). The challenge route was then modified to
intravenous administration of defined numbers of isolated sporo-
zoites. Intravenous injection of 2,500 sporozoites successfully in-
fected all inoculated mice (Table 1, experiment II), with patency
typically being observed by 6 days postchallenge (Table 1, experi-
ments III and IV). The BALB/c strain was more resistant to Tr P.
berghei parasites than were C57BL/6 mice and required a 4 to 5
times greater sporozoite dose than did the C57BL/6 strain. Based
on these data, all subsequent challenge experiments were per-
formed with C57BL/6 mice, using an intravenous dose of 2,500 Tr
P. berghei sporozoites.
Utility and validity of the Tr P. berghei model. A major goal of
this study was to establish the effectiveness of the Tr P. berghei
sporozoite model for the down-selection of different CSP-based
vaccine antigens. To accomplish this, the following four closely
related PfCSP constructs were prepared and tested: construct
N-(NANP)19-C contained the N-terminal region, 19 repeats, and
the C-terminal cysteine-rich region; construct N-(NANP)5-C
contained the N-terminal region, 5 repeats, and the C-terminal
region; construct (NANP)18-C contained 18 repeats and the C-
terminal region; and construct Cterm contained only the C-ter-
minal region of PfCSP (Fig. 2A and B). Groups of nine mice re-
ceived three intraperitoneal vaccinations of 2.5 g antigen
formulated with Montanide ISA720, at 2-week intervals. At 2
weeks after the third vaccination, mice were challenged with 2,500
Tr P. berghei sporozoites. Antibody titers were measured against
the repeat peptide (NANP)6 or the nearly full-length construct
N-(NANP)19-C protein coated onto ELISA plates.
As expected, the 5-repeat-containing construct induced lower
repeat-specific antibody titers than did constructs that contained
either 19 or 18 repeats (Fig. 2C and D). Interestingly, the
(NANP)18-C construct lacking the N terminus exhibited faster
kinetics of repeat-specific antibody acquisition after the second
vaccination than did the constructs that contained the N-terminal
region [N-(NANP)19-C and N-(NANP)5-C] (Fig. 2C). Similarly,
after the third vaccination, the magnitude of repeat-specific anti-
body levels in the (NANP)18-C-immunized group was greater
than that observed for the N-(NANP)19-C- and N-(NANP)5-C-
immunized groups (P  0.02 and 0.0001, respectively) (Fig. 2D).
The presence of the N-terminal region, however, did not glob-
ally reduce the immunogenicity of the N-(NANP)19-C and
N-(NANP)5-C constructs, as their group titers were similar to the
(NANP)18-C-induced titers when measured against the nearly
full-length CSP and Cterm plate antigens (P  0.2 for all compar-
isons) (Fig. 2D). Upon challenge with Tr P. berghei parasites, none
of the adjuvant control-, N-(NANP)5-C-, or Cterm-vaccinated
mice were protected (Fig. 2D, open triangles). In contrast, 4 of 9
N-(NANP)19-C-vaccinated mice and 4 of 9 (NANP)18-C-vacci-
nated mice were protected.
Titration of vaccine-induced protection. Groups of mice re-
ceived, at 2-week intervals, three intraperitoneal injections of in-
cremental doses of N-(NANP)19-C protein formulated with Mon-
tanide ISA720. The geometric mean antibody titers against all
three plate antigens at 2 weeks after the third vaccination increased
with increasing antigen dose (Fig. 3A). Mice were challenged with
2,500 sporozoites 2 weeks after the third vaccination. While no
protection was observed in the adjuvant control group, 1 of 6 mice
in the 1-g-dose group, 5 of 7 mice in the 2.5-g group, 3 of 7
mice in the 5-g group, and 7 of 7 mice in the 10-g group were
protected. Hence, the degree of protection increased with escalat-
ing antigen dose.
Association between antibody titers and protection against
Tr P. berghei. IgG subclasses and antibody avidity were measured
using the sera of individual mice from the various immunization
regimens. The protection status of the mice correlated with anti-
body titers against the nearly full-length protein and the repeat
peptide. As seen in Fig. 3B, 70% of the mice with ELISA titers of
10,000 against both the full-length and repeat antigens were
protected, in contrast to only 28% protection for mice with low
repeat-specific antibody titers and 21% protection for mice with
low antibody titers to both full-length and repeat antigens. Mice in
the three highest-dose groups (10, 5, and 2.5 g CSP) were tested
for antibody avidity. The avidity index was associated with pro-
tection, as 100% of mice with avidity index values of 80% and
full-length antigen ELISA titers of 10,000 were protected (Fig.
3C). Low levels of IgG2 induced by Montanide ISA720 formula-
tions precluded any correlation of subclasses with protection.
Biological activity of CSP-specific antibodies. Antibodies
against the N-(NANP)19-C protein showed positive reactivity
with fixed sporozoites by indirect immunofluorescence assay
(IFA), and pooled sera showed increasing IFA titers with escalat-
ing antigen dose (Fig. 4A and B). Antibodies after N-(NANP)19-C
immunization showed positive reactivity with an 60-kDa band





No. of mice that were:
Mean day
of patencyChallenged Infected
I 5,000 s.c. 7 1 8
7,500 s.c. 7 1 5
II 10,000 s.c. 7 5 6.3
2,500 i.v. 7 7 5.5
III 2,500 i.v. 7 7 5
1,000 i.v. 7 7 5
IV 2,500 i.v. 10 10 5.2
1,000 i.v. 10 9 5.4
a The sporozoite dose required for 100% infectivity in mice was established with
subcutaneous (s.c.) or intravenous (i.v.) injection of sporozoites. Shown are the
number of challenged mice, the number of infected mice (determined by patent
parasitemia in the blood), and the mean day of patency for each group.
Porter et al.
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on a Western blot against an extract of sporozoite-infected mos-
quito salivary glands (Fig. 4C). In a sporozoite invasion inhibition
assay, anti-N-(NANP)19-C serum (1:100 dilution) caused 90%
inhibition of sporozoite invasion of HepG2-A16 cells, compared
with 20% inhibition by normal mouse serum (Fig. 4D). Inhibi-
tion of sporozoite invasion activity increased with the antigen
dose, and 90% inhibition was observed using a serum pool from
the 10-g N-(NANP)19-C group, in which all of the mice were
protected (Fig. 4E).
Passive transfer of PfCSP-specific antibodies confers pro-
tection in the Tr P. berghei challenge model. Mice were ad-
ministered purified rabbit IgG against the N-(NANP)19-C vac-
cine and were challenged with 2,500 Tr P. berghei sporozoites.
All five mice that received anti-apical membrane antigen 1 IgG
developed parasitemia by day 5, while 3 of 5 mice that received
anti-CSP IgG were protected through day 14 postchallenge. In
another experiment, Tr P. berghei sporozoites were preincu-
bated with a 1:4 dilution of either mouse serum against
N-(NANP)19-C or control normal mouse serum. After a 5-min
incubation at 37°C, 3,000 sporozoites were injected intrave-
nously into each of three naive C57BL/6 mice. Two of three
mice in the anti-CSP group were protected through day 14,
FIG 2 Protection data on various PfCSP constructs. (A) Four constructs were expressed in E. coli, two of which included the N- and C-terminal regions and either
19 or 5 of the 38 NANP repeats of 3D7 P. falciparum CSP. A third construct contained 18 NANP repeats and the C-terminal region, and a fourth construct
(Cterm) contained only the C-terminal region. AA, amino acid; GPI, glycosylphosphatidylinisotol. (B) Coomassie blue-stained gel of purified proteins separated
through nonreduced SDS-PAGE. Lane 1, N-(NANP)19-C; lane 2, (NANP)18-C; lane 3, N-(NANP)5-C; lane 4, Cterm; M, markers. (C) Mean ELISA endpoint
titers against the repeat and nearly full-length constructs, measured 2 weeks after each vaccination. (D) Titers of individual mice in each group measured against
the (NANP)6 peptide, the nearly full-length protein, or the Cterm protein coated on plates. Geometric mean titers 	 95% confidence intervals are shown. o, mice
protected against Tr P. berghei challenge; , nonprotected mice.
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while all three control mice tested positive by day 6 postchal-
lenge.
DISCUSSION
There is substantial evidence that antibodies and T-cell-mediated
immune responses to CSP can protect against the pre-erythrocytic
stage of malaria (14). Owing to the escalating costs and regulatory
constraints associated with human vaccine trials and due to the
limitations of primate models of P. falciparum sporozoite chal-
lenge (7–9), there is an urgent need to develop rodent models for
the routine down-selection of second-generation vaccine formu-
lations of PfCSP vaccines. Here we present studies that led to the
optimization of one such rodent challenge model, based on trans-
genic P. berghei parasites that express full-length PfCSP (4). Our
data showed that this model can distinguish between the protec-
tive efficacies of several closely related CSP antigens, using a highly
stringent endpoint of sterile protection following intravenous in-
jection of sporozoites.
A notable area of concern with parasites that are transgenic for
full-length CSP is reduced sporozoite salivary gland invasion. Ro-
dent parasites expressing either Plasmodium falciparum or avian
Plasmodium gallinaceum CSP develop normally in the midgut yet
show significantly reduced salivary gland burdens in mosquitoes.
In such studies, the N-terminal and repeat regions of CSP were
specifically implicated in migration to the salivary glands (15, 16).
We found in our studies that switching from blood-stage passage
to more-natural, vector-borne, mosquito-to-mouse passage
yielded an adapted line of Tr P. berghei that routinely produced
sufficient (although still relatively low) numbers of infective
sporozoites for challenge experiments. Other criteria for success-
ful challenge included sporozoite yields of 1,000 per mosquito,
addition of 5% freshly collected mouse serum to the dissection
medium, minimization of the dissection time to under 1 h, and
storage of dissected sporozoites on ice until injection.
The observation that constructs containing the N terminus
induced lower levels of repeat-specific antibodies than did those
lacking the N terminus requires further investigation, as it may
reflect the shielding of CSP domains by the N-terminal region that
is known to occur during sporozoite passage from the mosquito to
the liver (17). Although the relative immunogenicity of different
CSP regions may be different in humans and mice, it is notable
that the only successful CSP-based malaria vaccine, RTS,S, also
lacks the N-terminal region. Thus, these observations in mice
might have implications for improving CSP vaccine design (18).
Although the C-terminal region of P. berghei CSP has been asso-
ciated with protection in mice (19, 20), our C-terminal construct
of PfCSP did not confer protection against a Tr P. berghei chal-
lenge. This result was reminiscent of a human trial in which a
FIG 3 Protection data with incremental doses of PfCSP. (A) Endpoint titers for mice vaccinated with increasing doses of N-(NANP)19-C protein, measured 2
weeks after the third dose, against the (NANP)6 repeat peptide, the nearly full-length N-(NANP)19-C protein, or the Cterm protein coated on ELISA plates.
Geometric means 	 95% confidence intervals are shown. o, protected mice; , nonprotected mice. (B) Endpoint titers for mice from the construct and
dose-titration experiments, 2 weeks after the third vaccination. Full-length CSP ELISA titers were plotted against the repeat peptide ELISA titers. P, protected
mice; NP, nonprotected mice. Inset, percentage of mice protected in each quadrant. (C) Nearly full-length ELISA titers for N-(NANP)19-C-immunized mice,
from the construct and dose-titration studies, plotted against the respective avidity index values.
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repeatless CSP construct did not protect the vaccinees (21). Doud
et al. have recently shown that key epitopes in the C-terminal
region involve noncontiguous residues of the molecule (22). It is
possible that the isolated C-terminal protein used for immuniza-
tion in our study did not adopt the same conformation as the
C-terminal region in the intact CSP molecule. Additionally, it is
noteworthy that several mice with low repeat-specific antibody
titers were protected in the present study, as is often observed with
RTS,S-immunized humans. Although cellular immune responses
to CSP were not measured, T-cell epitopes in the N- and C-termi-
nal regions of CSP might have contributed to protection (6, 19), as
observed by others using CSP-transgenic parasite models (11, 23).
In conclusion, we report sterile protection by recombinant
PfCSP vaccines against a full-length PfCSP-transgenic mouse par-
asite challenge. The protection was dependent on the antigen dose
and the nature of the CSP immunogen. In support of our obser-
vations, it is noteworthy that, during the course of our study, Kaba
et al. reported using the same Tr P. berghei parasite line to monitor
protection induced in mice following immunization with a nano-
particle vaccine expressing B-cell and CD8 T-cell epitopes from
the PfCSP (23). Although the biological relevance of this mouse
protection model with respect to human vaccine development
remains to be confirmed, sterile protection as the efficacy end-
point provides a means to evaluate PfCSP-based vaccines rapidly
for future human trials.
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